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started PUVA treatment by the age of
25 years and were o40 years in the
1990s (mean age starting PUVA¼19
years) had a significantly higher risk of
BCC than Nambour patients of compar-
able age (IRR (incidence rate ration)¼
2.64, 95% CI (95% confidence
interval)¼ 1.04–6.70).
When each tumor is counted, the
incidence of tumors was far higher in
the PUVA cohort than in the Nambour
cohort (age-adjusted incidence 239 vs
51 per 1,000 patient-years, Po0.001).
The incidence of BCC (tumor counts)
was significantly higher in patients with
more than 200 PUVA treatments than
those with fewer treatments (IRR¼ 3.1,
95% CI¼ 2.74–3.54).
Table 2 provides the anatomic dis-
tribution of tumors in both cohorts. The
incidence of BCC on the trunk and
lower extremities was more than six
times higher for PUVA patients than for
Australians.
In contrast to the far lower incidence
of BCC in the United States’ general
population, North American patients
who use PUVA and live in temperate
climates have at least as high a risk of
developing at least one BCC as seen in
a fairer-skinned population living in a
subtropical Australia. The greatest in-
crease in risk was seen among those
who started PUVA treatment before age
25 years. The average number of
tumors per patient who developed at
least one BCC was about three times
higher for PUVA patients than for
Australians (Tables 1 and 2). Earlier
reports suggest that the increase in BCC
among Australians is nearly 10 times
that of residents in United States, a
finding markedly different from the
experience of the PUVA cohort re-
ported here (Stern, 1999). A compar-
ison of our data and population-based
data from Australia provides a context
for informing clinicians and advising
patients about the long-term risk of
BCC with PUVA, particularly for those
exposed when young.
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TO THE EDITOR
As a biostatistician, I read the article by
Lu et al. (2008) with concern. I wish to
raise several issues, some echoed by
other commentators (Ellefson, 2009;
Staeb et al., 2009).
ISSUE 1
I have questions about the design of
the study. Was randomization used
to select treatment groups? If so,
it is important that randomization
was carried out at the end—not
the beginning—of the pre-treatment
period. If mice were separated into
groups before this time, it is possible
that this part of the experiment
induced differences before treatment
application.
Table 2. Anatomic distribution and incidence of BCCs in PUVA cohort
1990–1999 and Queensland (Australia) 1997–2006
PUVA cohort Australia1
Anatomical site
No. of tumors
(%) Incidence rate2 No. of tumors (%) Incidence rate2
Head and neck 488 (51) 122 379 (57) 29
Trunk 284 (30) 71 111 (17) 9
Upper extremities 77 (8) 19 118 (18) 9
Lower extremities3 108 (11) 27 54 (8) 4
All sites 959 239 662 51
BCC, basal cell cancer; PUVA, psoralens plus UVA.
1Richmond-Sinclair et al. (2008).
2BCCs per 1,000 person-years.
3Includes buttocks and hip.
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ISSUE 2
Were the investigators, who adjudi-
cated the occurrence, number, and size
of tumors, blinded? This is particularly
important given apparent variation
across identical experiments.
ISSUE 3
Apparently not all mice were available
for assessment (Tables 2–5). For exam-
ple, only 25 mice had results in the
Custom Blend group, suggesting that
17% of the mice either never started on
treatment or were lost to follow-up.
What was the reason for exclusions?
(These mice were assumed to have died
by Ellefson, 2009). Removing mice
because of tumor development and/or
death during pre-treatment biases sub-
sequent comparisons if exclusions oc-
curred unequally across groups. Similar
bias arises if mice were removed after
treatment because of adverse events
possibly related to the risk of tumor
formation. In either case, groups with
larger number of removals might then
show artificially low rates of tumor
formation with high-risk mice selec-
tively excluded. This is a concern
in Experiment 2, where the largest
number of removals came from
the Untreated and Custom blend
groups, on the lower end of outcome
measures.
ISSUE 4
It is not clear to me why the cumulative
incidence curves for the Untreated and
Dermovan groups (Figures 1a and d)
decline from weeks 9–13, impossible
for Kaplan–Meier estimators. Further,
plotted numbers in Figure 1c do
not always agree with Table 4, the
latter reporting cumulative incidence of
77% for the Water control group
where the plotted point (Figure 1c) is
above 80%.
ISSUE 5
There are no apparent differences in
percent of mice developing tumors,
except for Dermabase (Figure 1c) and
Dermovan (Figure 1d) comparisons
with Water control (Experiment 2).
The P-value 0.003 associated with
Figure 1c, presumably from a log-rank
test, is surprising, given cumulative
incidences in the Dermabase, and
Water control, groups of 90 and 77%,
respectively (Table 4). A simple 2 2
table comparison of these incidences
among 29 and 30 mice, respectively,
produces a P-value 0.2 using the
standard w2-test. This asymptotic test
depends on large samples (does as log-
rank testing); the exact test, not depen-
dent on such approximations, yields a
P-value 0.3. However, neither of these
tests uses occurrence time information
used by log-rank calculations. Approxi-
mately reconstructing tumor incidence
over time (Figure 1c), a log-rank test
yields a P-value 0.06. Ignoring the
variation among these various P-values,
none of them are compatible with
0.003.
ISSUE 6
The variables, number of tumors, and
tumor volume per mouse are not
explicitly defined. Apparently, ‘‘tumors
per mouse’’ includes mice with no
tumors (Table 4), as now confirmed by
the authors (Conney et al., 2009).
Comparison of the mean of this random
variable across groups is therefore
influenced by differences in percen-
tages of mice that ever develop tumors,
rendering comparative interpretation of
‘‘tumors per mouse’’ problematic. For
example, the ‘‘tumors per mouse’’
comparison between the Dermabase
and Custom blend groups of Experi-
ment 2 (Table 4) uses averages 7.52 and
4.88, respectively. The average number
of tumors per mouse, given that at least
one tumor developed, is actually 8.4 for
Dermabase, and 6.8 for Custom Blend.
These numbers (with standard devia-
tions approximately 1.2) are subs-
tantially closer, suggesting that compar-
isons of ‘‘tumors per mouse’’ are
overstated. An identical comment applies
to ‘‘tumor volume per mouse’’ (Table 5).
ISSUE 7
Further, can the authors discuss the
adequacy of the Poisson model for the
number of tumors per mouse (Conney
et al., 2009), as this is a very restrictive
statistical assumption (more restrictive
than the two-sample t-test used by
Staeb et al., 2009), particularly an issue
when structural zeros (the mice with no
tumors) are automatically included with
positive counts.
ISSUE 8
In Tables 4–5, the Water and Untreated
‘‘control’’ groups are combined,
presumably to allow for additional pre-
cision. However, other commentators
have raised the possibility of similarly
combining the Dermabase groups (and,
similarly, the untreated groups) from
Experiments 1 and 2, apparently iden-
tical experiments. Comparing the results,
the average number of tumors per mouse
under Dermabase is 12.39 (SE¼1.53) in
Experiment 1 (Table 2), but only 7.52
(SE¼1.18) in Experiment 2 (Table 4), a
difference of about 4 SEs. This between-
experiment variation is much greater
than the variation between the Derma-
base and Water (or Untreated) groups in
Experiment 2, and is statistically signifi-
cant: two apparently equivalent experi-
ments produce noticeably different
results. This source of variation is not
accounted for by the separate analyses of
Experiments 1 and 2.
ISSUE 9
Incorporating between-experiment var-
iation is desirable, likely substantially
increasing comparative P-values. In one
response, the authors note that the
differences between experiments were
attributable to them being conducted
‘‘more than a year apart’’ (Conney
et al., 2009). Unfortunately, this does
not directly address the reproducibility
of Experiment 2; without further details,
one must assume that differences be-
tween the experiments are because of
random variation.
ISSUE 10
It would be helpful to know more
explicitly the random effects model used
for analysis and further assumptions
about additional within-mouse correla-
tion assumptions. As no intercepts were
used, what random slopes were consid-
ered? A specific choice of random effects
necessarily induces a particular within-
mouse correlation structure. I would
have preferred standard regression tech-
niques with a ‘‘working’’ within-mouse
correlation structure, with estimation
using generalized estimating equations,
as coefficient estimates are more robust
than those from mixed effects models,
where unverified assumptions can sub-
stantially influence results.
www.jidonline.org 2317
NP Jewell
Tumorigenic Effect of Moisturizing Creams
ISSUE 11
Estimated percent increases (in parenth-
eses, Tables 2–5) are highly variable
representing ratios of quantities that
themselves vary substantially. As such,
it would be helpful to see confidence
intervals reported (including allowance
for between-experiment variation). This
issue arises in the Abstract, where
estimated percent increases are reported
without uncertainty information. This is
particularly crucial as quite different
increases (or decreases) arise with a
different ‘‘control’’ comparison. For ex-
ample, the appropriate average number
of tumors per mouse (if tumors occur—
see above) for the Eucerin group (Experi-
ment 2) is 7.43, and 8.04 for the
Untreated group of Experiment 1. This
‘‘just-as-appropriate’’ comparison yields
a decrease in number of tumors per
mouse of 8%, not the increase of 24%
reported in the Abstract.
ISSUE 12
Finally, is it not possible that any
apparent difference between treat-
ment groups in the number (volume)
of tumors observed might be because of
effects after at least one tumor has
occurred—the latter attribute barely
varying across groups—rather than aris-
ing from any mutagenic or carcinogenic
effects? This concern reinforces
what other commentators have noted
about the misleading nature of the
article’s title (Ellefson, 2009; Staeb
et al., 2009).
There are many fine experimental
papers in the literature that generate
similar data and that successfully han-
dle most of the issues raised here. See,
for example, the study by Lerche et al.,
2008. Unfortunately, given the con-
cerns raised above, I join previous
correspondents in asserting that the
authors’ interpretations of their results
are not scientifically justifiable.
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TO THE EDITOR
Dr Nicholas P. Jewell expresses several
concerns about our publication ‘‘Tu-
morigenic effect of some commonly
used moisturizing creams when applied
topically to UVB-pretreated high risk
mice’’ (Lu et al., 2008). Many of these
concerns were raised earlier (Ellefson,
2009; Staeb et al., 2009) and answered
(Conney et al., 2009a; Conney et al.,
2009b). We answer Dr Jewell’s con-
cerns as follows:
RESPONSE TO ISSUE 1
All randomizations were carried out
after the completion of the UVB pre-
treatment. It might not be clear or
explicit enough, but we did imply this
order in our paper (Materials and
Methods, descriptions of Experiments
1 and 2) by stating ‘‘In experiment 1,
we treated 60 female SKH-1 mice with
UVB y for 20 weeks. y UVB irradia-
tion was stopped, and half of the mice
were treated with 100 mg Dermabase
once a day, yfor 17 weeks, and the
control group was untreated.’’ A similar
description was given for experiment 2.
We add that this is carried out routinely
in our laboratory, as indicated in our
earlier publications. See Proc Natl Acad
Sci USA 99:12455–12460, 2002 and
Carcinogenesis 28:199–206, 2007 (cited
in our manuscript) as well as other papers
from our laboratory. For experiment 1,
we randomized 58 UVB-pretreated
tumor-free mice (29 in each group). In
experiment 2, we randomized all 210
UVB-pretreated tumor-free mice (30 per
group).
RESPONSE TO ISSUE 2
Although the topical treatment of mice
and the collection of data for Figure 1
were not blinded, they were performed
by a lab technician (J.-G. Xie) who had
no scientific interest in the results. The
histological evaluation of tumors (data
in Tables 2–5) was blinded so that the
histologist did not know which group
or mouse was being evaluated, as we
have performed in earlier studies (see
Carcinogenesis 28:199–206, 2007; cited
in our manuscript).
We should point out that experi-
ments 1 and 2 were similar in their
procedures, but they were not identical.
In fact, they were separated by more
than a year and one was a pilot study,
whereas the other was confirmatory
(see additional response later). Although
Dr Jewell believes there was variation
between our two experiments, both
experiments demonstrated a tumorigenic
effect of Dermabase in UVB-pretreated
mice (discussed later).
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